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Inherited retinal dystrophies present extensive phenotypic and genetic heterogeneity, posing 
a challenge for patients’ molecular and clinical diagnoses. In this study, we wanted to clinically 
characterize and investigate the molecular etiology of an atypical form of autosomal recessive retinal 
dystrophy in two consanguineous Spanish families. Affected members of the respective families 
exhibited an array of clinical features including reduced visual acuity, photophobia, defective color 
vision, reduced or absent ERG responses, macular atrophy and pigmentary deposits in the peripheral 
retina. Genetic investigation included autozygosity mapping coupled with exome sequencing in the 
first family, whereas autozygome-guided candidate gene screening was performed by means of 
Sanger DNA sequencing in the second family. Our approach revealed nucleotide changes in CDHR1; 
a homozygous missense variant (c.1720C > G, p.P574A) and a homozygous single base transition 
(c.1485 + 2T > C) affecting the canonical 5’ splice site of intron 13, respectively. Both changes co-
segregated with the disease and were absent among cohorts of unrelated control individuals. 
To date, only five mutations in CDHR1 have been identified, all resulting in premature stop 
codons leading to mRNA nonsense mediated decay. Our work reports two previously unidentified 
homozygous mutations in CDHR1 further expanding the mutational spectrum of this gene.
Inherited retinal dystrophies (IRDs) encompass a large group of progressive neurodegenerative diseases 
with functional consequences on retinal physiology that lead eventually to significant visual handicap. 
IRDs can be broadly characterized on the basis of the sequential order and relative severity of the dys-
function or loss of either photoreceptors, and include cone dystrophies (CD), cone–rod dystrophies 
(CRDs) and retinitis pigmentosa (RP)1. When primary cone dysfunction (CD/CRDs) is present, initial 
symptoms include early and progressive loss of central visual acuity, defective color vision and photopho-
bia, whereas RP causes in patients night blindness as the first noticeable symptom2–4. Genetically, IRDs 
display all Mendelian inheritance patterns, i.e. autosomal recessive (ar), autosomal dominant (ad), or 
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X-linked (Xl). To date, mutations in more than 105 genes (RetNet; http://www.sph.uth.tmc.edu/retnet/) 
have been identified to cause several forms of inherited retinal dystrophies. IRDs are also characterized 
by genetic and clinical overlap, for which for instance mutations in specific genes can result in different 
diseases4,5.
Functionally, a significant proportion of genes associated with IRDs encode proteins with key roles 
in the maintenance of photoreceptor structure and integrity. One of them is the cadherin-related family 
member 1 (CDHR1, OMIM *609502, formerly known as PCDH21), a member of the calcium-dependent 
cadherin superfamily of homophillic cell-adhesion proteins. Structurally, these molecules are integral 
proteins, primarily characterized by the presence of multiple (up to 34) cadherin repeats, i.e. large 
extracellular calcium (EC) binding domains that determine individual cadherin’s functional profile6,7. 
Cadherins are evolutionary conserved, and even subtle aminoacid changes have been found to impact 
their adhesive binding specificity with protein partners. Of note, mutations in four cadherin family mem-
bers (among which CDHR1) have been identified to cause retinal dystrophy8–11.
CDHR1 is composed of six cadherin repeats, one transmembrane, and one intracellular domain. The 
protein is present in a small fraction of neuronal tissues, including the olfactory bulb and the retina12,13. 
Within the retina, CDHR1 appears to exert its function at the base of the photoreceptor’s outer segment, 
and especially at the junction between the inner- and outer segments, opposite to the connecting cil-
ium14,15. A cdhr1-/- mouse model exists, for which disruption of the gene leads to compromised structures 
of cone and rod outer segments and progressive photoreceptor degeneration15, making CDHR1 a prime 
candidate disease gene for IRDs in humans.
Historically, Bolz and colleagues16 proceeded first with a comprehensive screening of the CDHR1 
gene in a large cohort of IRD patients and identified two missense variants with inconclusive pathogenic 
potential, since they were heterozygous with no second pathogenic allele in either of the carrier persons. 
To date, further studies have revealed only a handful of cases with mutations in CDHR1 causing either 
arCRD or a clinically related form of retinopathy, sometimes referred to as “CDHR1-related retinopa-
thy” affecting primarily but not solely the cone photoreceptors2,11,17–19. The majority of CDHR1 muta-
tions, ascertained from populations with different ethnic background, likely result in nonsense mediated 
mRNA decay and thus in reduced or in no protein content in affected individuals. In this work, we 
describe two consanguineous Spanish families that were investigated by combining autozygosity map-
ping with candidate gene analysis, either by using exome sequencing or “classical” sequencing analysis 
by the Sanger method. Patients also underwent detailed clinical evaluation by using retinal imaging 
and electroretinography techniques. Finally, our study yielded two previously-undescribed homozygous 
mutations in CDHR1.
Methods
Patients. Six members of family RP-0763 and four members of RP-0043, both from Spain, were ascer-
tained for this study (Fig. 1). As controls, 165 healthy and unrelated subjects from Spain were included.
This study was carried out in accordance with the tenets of the Declaration of Helsinki and was 
approved by the Institutional Review Boards of the University of Lausanne, Switzerland and the Clinical 
Research Ethics Committee of the Fundacion Jimenez Diaz University Hospital in Spain. Written 
informed consent was obtained from the subjects who participated in this study and donated their blood 
for research. Each individual was anonymized by assigning to them a numeric ID; confidentiality and 
protection of data were ensured by applying international recommendations and current Spanish legis-
lation (Ley de Investigacion Biomedica 14/2007 and LOPD).
Clinical examination. Affected individuals underwent a full ophthalmic examination including eval-
uation of best-corrected visual acuity (BCVA), intraocular pressure, ocular motility, pupillary reaction, 
biomicroscopic slit-lamp examination, and dilated fundus examination. The color vision was examined 
by the 28 HUE Farnsworth or Ishihara tests. Visual function was evaluated by static perimetry, optical 
coherence tomography (Cirrus, Carl Zeiss Meditec Inc., Dublin, CA) and Ganzfeld electroretinography, 
according to the guidelines of the International Society for Clinical Electrophysiology of Vision.
Genetic analysis. Genomic DNA was extracted from 1 ml of whole blood using an automated DNA 
extractor (Magna Pure Compact, Roche, Basel, Switzerland) following the manufacturer’s instructions.
Whole genome homozygosity mapping was performed using high-resolution commercial SNP arrays 
from Affymetrix (Affymetrix, San Diego, CA, USA) (Genome Wide Human SNP array) and Illumina 
(Illumina, Santa Clara, CA, USA) (Omni Whole Genome arrays HumanCytoSNP-12) for RP-0763 and 
RP-0043, respectively. Arrays were processed according to the manufacturer’s protocols. Genome-wide 
autozygosity mapping was performed using the Linkage Disequilibrium - Hidden Markov Model algo-
rithm (LD-HMM)20 through the dCHIP software21.
For mutation analysis, specific primers were used to PCR-amplify the entire CDHR1 open read-
ing frame (ORF), consisting of 17 exons and of their exon-intron boundaries. Primer sequences were 
described previously11,16, except for exon 15, for which a distinct primer pair was designed (forward: 
5′ -ACACCCATGCCTATGTGCTC-3′ , reverse: 5′ -TATCTCTTGGAGCTGCTGGA-3′ ). PCR amplifica-
tion proceeded under standard conditions.
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Figure 1. Pedigrees of patients analyzed and mutations identified in this work. (a) Pedigree of family 
RP-0763. The parents are first cousins. Open and closed symbols represent unaffected and affected 
individuals, respectively. m1/m1 refers to the homozygous presence of the mutation c.1720C> G in CDHR1 
(NM_033100.3), whereas m1/+ refers to its heterozygous presence. The arrow indicates the proband for 
this family. (b) Chromatograms of Sanger DNA sequencing surrounding the CDHR1 variant c.1720C> G 
are shown for patient II:2 and the healthy carrier individual II:1. (c) Pedigree of family RP-0043 in which 
parents are also first cousins. m2/m2 refers to the homozygous presence of the mutation c.1485 + 2T> C 
in CDHR1 (NM_033100.3), whereas m2/+ refers to its heterozygous presence. The arrow indicates the 
proband for this family. (d) Chromatogram of Sanger DNA sequencing surrounding the CDHR1 variant 
c.1485 + 2T > C is shown for patient II:1 and the healthy parent I:1.
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Mutation screening was performed by direct Sanger sequencing with the Big Dye terminator cycle 
sequencing kit on an ABI 3130xl Genetic Analyzer (PE Applied Biosystems, Foster City, CA, USA). The 
DNA control samples for the c.1720C > G mutation were screened with a restriction endonuclease-based 
assay with AciI (New England Biolabs, Beverly, MA, USA).
In addition, DNA control samples for c.1485 + 2T > C in exon 13 were screened by High Resolution 
Melting (HRM) analysis according to an optimized protocol. Real-time PCR and HRM were consecu-
tively done on a LightCycler 480 Real-Time PCR System (Roche, Basel, Switzerland) in one single run, 
and all reactions were performed in duplicate. PCR and HRM conditions are available on request. PCR 
products displaying abnormal HRM profiles were further analysed by direct Sanger sequencing.
Exome sequencing was performed in individual II:2 from family RP-0763 (Fig.  1). Exome capture 
and library construction were performed using the Agilent SureSelect Human All Exon v4 Kit (Agilent, 
Wokingham, UK) using 6 μ g of genomic DNA. Libraries were sequenced on an Illumina HiSeq 2000 
(Illumina, San Diego, CA) generating 100 bp paired-end reads. Reads were aligned to the hg19 human 
reference sequencing using Novoalign (Novocraft, Selangor, Malaysia) version 2.05. The Genome Analysis 
Toolkit (GATK)22 was used for refining mapping around small insertions/deletions, base quality score 
recalibration and variant calling. In order to detect the potential disease-causing variant(s), a proprietary 
filtering pipeline was implemented based on homemade Perl scripts as previously described23. Finally, 
variants were prioritized on the basis of their presence in shared regions of autozygosity, taking into 
assumption the inheritance of identical genotypes from a single founder from both related patients.
In silico assessment of mutation pathogenicity. The potential consequences of the mutation 
c.1485 + 2T > C on the normal splicing of its neighboring exons were analyzed in silico using the NetGene 
2 Server24 and Human Splicing Finder25. In addition Polymorphism Phenotyping v2 (Polyphen-2)26, 
Sorting Intolerant from Tolerant (SIFT)27 and Mutation Taster28 were used in order to evaluate the puta-
tive pathological nature of the missense variant that we report in this study.
Amino acid conservation. CDHR1 protein sequences from different species including human 
(H. sapiens, NP_149091.1), mouse (M. musculus, NP_570948.1), cow (B. taurus, NP_777248.1), 
chicken (G. gallus, NP_001001759.1), Xenopus (X. tropilcalis, XP_002933948.2) and zebrafish (D. rerio, 
NP_001005402.1) were aligned using the CLC Genomics Workbench (CLCbio, Qiagen, Boston, USA) in 
order to check the evolutionary conservation of their substituted amino acid residues.
Results
Clinical examination. For the index case (II:2) of family RP-0763 (Fig.  1) the initial diagnosis was 
made at the age of 34. Photophobia, photopsia and color vision disturbances were the first noticeable 
symptoms, followed by night blindness and peripheral visual field loss. At the time of the last ophthal-
mologic examination (45 years), the best-corrected visual acuity was 0.8 for the right eye (OD) and 0.7 
for the left eye (OS). Posterior subcapsular cataract was found. The 28 HUE Farnsworth test showed 
nonspecific mild abnormalities. She presented with a tubular visual field with a small island of central 
vision accompanied by temporal island at the age of 42 being reduced to absolute scotoma at the age 
of 45 (Supplementary Figure S1). The fundus showed a pale disc, narrowed vessels, scarce bone spicule 
pigmentation in the mid-periphery, yellowish dots in macula and macular retinal pigment epithelium 
degeneration (Fig. 2). Full-field electroretinogram was nonrecordable and for the multifocal (mf) elect-
roretinography the amplitude was decreased in all records (Fig. 3). The OCT showed bilateral thinning 
of the fovea (Fig. 2). Clinical data are summarized in Table 1. The affected sibling (II:3) was not available 
for the ophthalmic examination.
The initial diagnosis of the index case (II:1) of family RP-0043 (Fig. 1) was made in her third decade 
of life. Night blindness and field constriction were the first noticeable symptoms. At 33 years of age, 
visual field was symmetrically reduced to 10 degrees and the visual acuity was 0.2 OD and 1 OS. The 
patient was amblyopic since childhood. Fundus examination showed pale discs, narrow vessels, bone 
spicule pigmentation in the mid-periphery and a bull’s eye macular phenotype resulting in annular ret-
inal pigment epithelium (RPE) atrophy with central sparing of the fovea. Full-field electroretinogram 
was non-recordable and in multifocal electroretinography (mfERG) the amplitude was diminished in all 
instances. After further ophthalmologic examination (at age 49 years) the patient showed light percep-
tion visual acuity for both eyes (Table 1).
For the affected sibling (II:2), the initial diagnosis was made at the age of 32. Visual field presented 
central scotoma and the visual acuity was 0.12 OD and 1 OS. The refractive error was − 3 sphere, − 1.50 
cylinder OD and − 2 sphere OS. The 28 HUE Farnsworth test showed alterations in color vision. The 
fundus showed small optic papillae, unstructured macula and atrophy in the periphery (Table 1).
Genetic analysis. Both families reported in this study are consanguineous and retinal dystrophy 
segregates in an autosomal recessive mode. Based on this information, we performed genome-wide, 
SNP-based autozygosity mapping. Our analysis revealed several large autozygous regions that were 
shared among the affected siblings in the two families (Table 2). In particular, regions containing more 
than 300 consecutive homozygous SNPs, on average corresponding to a genomic size of 1 Mb or larger, 
were prioritized.
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In family RP-0763, autozygosity analysis resulted in five large autozygous regions (Table 2). The third 
largest autozygous interval, which encompasses a genomic region of 5.7 Mb on chromosome 10 (hg19: 
85.7-91. Mb) contains CDHR1. Following the evaluation of the exome sequencing data of patient II:2 
(family RP-0763) we identified a homozygous mutation c.1720C > G (p.P574A) in this gene.
Dideoxy DNA sequencing confirmed the presence of this variant which co-segregated with retinal 
dystrophy in the pedigree (Fig.  1). The mutation was not detected in 165 healthy control individuals, 
in an internal control cohort containing whole exome and/or whole genome sequencing data from 350 
unrelated individuals or in any other public database, including the one from 1000 Genomes Project29, the 
Exome Variant Server (EVS, http://evs.gs.washington.edu/EVS) and the Exome Aggregation Consortium 
Figure 2. Fundus photographs and optical coherence tomography (OCT) of affected individual II:2 
from family RP-0763. (a) Fundus photograph taken at the age of 45 (left and right eye) demonstrating 
a pale optic disc and attenuated blood retinal vessels. Macular involvement is noted with the presence 
of spotted hyperpigmentation (yellowish dots) and annular RPE with central sparing of the fovea (bull’s 
eye maculopathy). (b) Fundus photograph of the retinal periphery (left and right eye) demonstrating the 
presence of pigmentary changes in the form of scarce bone spicule pigmentation. (c) OCT of left and right 
eye demonstrating a decreased foveal depression.
Figure 3. Multifocal electroretinography (mfERG) of patient II:2 from family RP-0763, for the left (a) and 
right (b) eye. The mfERG shows a reduced amplitude in all records at the age 45.
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(ExAC, http://exac.broadinstitute.org), which contains sequencing data from more than 61,000 unrelated 
individuals. The homozygous p.P574A alteration affects a proline residue, fully conserved from fish to 
human (Fig. 4a), and is located in the fifth cadherin repeat (Fig. 4b). Furthermore, c.1720C is an evo-
lutionary highly conserved nucleotide with a phyloP score of 5.65 (threshold for significance > 0.95). 
Therefore, the substitution of an alanine for this proline residue is likely to affect the CDHR1 function. 
Furthermore, the in silico analysis of p.P574A using three different online tools predicted this mutation 
to be probably damaging by Polyphen (score 0.998), deleterious by SIFT (score 0.00) and disease causing 
by Mutation Taster (score 0.999).
In family RP-0043, autozygosity analysis resulted in seven large autozygous regions (Table  2). The 
largest autozygous interval, which encompasses a genomic region of 47 Mb (hg: 72-118.9 Mb) contains 
CDHR1. Several additional genes known to be involved in inherited retinal dystrophies were also within 
these intervals, namely LRAT underlying Leber Congenital Amaurosis (LCA)30 and AILP1 underlying 
LCA, juvenile RP and autosomal dominant CRD31,32. However, since the phenotypic picture of both 
Family  
Patient ID Genotype
First symptoms 
and course
BCVA 
OD/OS
Visual Field 
OD/OS ERG Fundus aspect
28 HUE 
Farnsworth or 
Ishihara test OCT
Additional 
findings
RP-0763: II:2 p.P574A/ p.P574A
Photophobia, 
photopsia 
and color 
disturbances  
(30 yrs), 
Progressive loss 
of VA (33 yrs), 
NB (33 yrs) and 
field constriction 
(34 yrs)
0.8/0.7
Tubular 
visual field 
with a small 
island of 
central 
vision and 
a temporal 
island 
(42 yrs). 
Absolute 
scotoma (45 
yrs)
Full 
field was 
non-re-
cordable 
and 
mfERG 
ampli-
tude was 
decreased 
in all 
records.
Pale optic 
disc, narrow 
vessels, scarce 
bone spicule 
pigmentation in 
mid-periphery, 
yellowish dots in 
macula and bull’s 
eye maculopathy
Non-specific mild 
abnormalities
Decreased 
foveal  
depression
Posterior 
subcapsular 
cataract
RP-0043: II:1 c.1485 + 2T> C/ c.1485 + 2T> C
NB (26 yrs) and 
field constriction 
(26 yrs)
0.2/1.0 
(49 yrs)
Tubular 
visual 
field with 
temporal 
islands
non-re-
cordable
Pale optic disc, 
narrow vessels 
and bone spicule 
pigmentation in 
mid-periphery
NCD NCD NCD
RP-0043: II:2 c.1485 + 2T> C/ c.1485 + 2T> C
Color 
disturbances and 
field constriction 
(32 yrs)
0.12/1.0
Relative 
central 
scotoma 
and some 
peripheral 
islands
NCD
Small optic disc, 
unstructured 
macula and 
atrophy in the 
periphery
Altered NCD
Superficial 
punctate 
keratitis
Table 1.  Clinical features of patients with mutations in CDHR1. ID, identification code; yrs, years; 
BCVA, best corrected visual acuity; OD, right eye; OS, left eye; ERG, electroretinogram; mf, multifocal; 
OCT, optical coherence tomography; NB, night blindness; VA visual acuity; RPE, retinal pigment epithelium; 
NCD, no clinical data.
Family Ranking Chr
Region of ho-
mozygosity
Region 
size
Number of 
genes
Known RD 
genes
RP-0763
1 1 53.8–81.1 27.34 220 RPE65
2 13 102.1–111.7 9.53 41
3 10 85.7–91.3 5.71 78 CDHR1, RGR
4 9 65.3–70.8 5.5 29
5 17 72.5–74.8 2.34 48
RP-0043
1 10 72–118.9 46.9 401 CDHR1
2 4 144.5–162.2 17.7 83 LRAT
3 10 14–27.8 13.8 78
4 19 36–38.5 2.5 84 AIPL1
5 3 95.6–97.4 1.8 2
6 22 43.9–45.2 1.3 17
7 4 183.7–184.7 1 11
Table 2.  Homozygosity mapping results in families RP-0763 and RP-0043. Chr, Chromosome; RD, 
Retinal degeneration. Regions of homozygosity and regions’ sizes are provided based on the human 
reference sequence (hg19) and are expressed in megabases (Mb).
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affected siblings is consistent with autosomal recessive retinal degeneration resembling the phenotypic 
spectrum elicited by CDHR1 mutations, we considered CDHR1 as a prime disease gene candidate to be 
screened in this family.
Figure 4. Amino acid sequence alignment of human CDHR1 in the area spanning the missense variant 
p.P574A and topology of the CDHR1 protein indicating the position of all reported mutations. (a) 
Amino acid sequence alignment of human CDHR1 with orthologous proteins from mouse, dog, cow, 
chicken, frog, and zebrafish. Ten upstream and 10 downstream amino acids from the missense variant 
P574A are depicted. Residues identical to the human sequence across all sequences are black on a white 
background whereas different amino acids are indicated in white on a grey background. The amino acid 
residue at the position of the missense change is indicated in bold. (b) Topology of the CDHR1 protein 
and the position all reported mutations. The intracellular domain (IC) is shown as a purple line; the 
transmembrane domain (TM) is indicated in a box with grey background. The ectodomains (EC) are 
indicated in red oval shapes with the linker regions as blue boxes in between the ectodomains. Mutations 
reported in previous studies are indicated depicted in black whereas mutations identified in this work are 
indicated in red.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:13902 | DOi: 10.1038/srep13902
Indeed, sequence analysis by the Sanger method of the gene’s ORF and intron-exon boundaries, ini-
tially in patient II:2, identified the homozygous nucleotide change c.1485 + 2T > C, which affects one 
of the two completely conserved nucleotides of the canonical 5' splice site of intron 13 and therefore 
is likely to have a major effect on CDHR1 splicing. The mutation was also present homozygously in 
the affected sibling and in heterozygous state in the healthy parents (Fig.  1). Similarly to c.1720C > G, 
the mutation was neither detected in control individuals, nor it has been reported present in the 1000 
Genomes Database or any other public database. It is of note that the exact same nucleotide position has 
been previously reported to be mutated in an Israeli Christian Arab family although the base substitution 
was different (c.1485 + 2T > G)17. In silico assessment of c.1485 + 2T > C using two distinct web-based 
platforms (NetGene 2 Server and Human Splicing Finder) predicts the practical abolishment of the 
donor splicing site (Table 3).
Discussion
In this study we identified two consanguineous Spanish families segregating autosomal recessive retinal 
degeneration and harboring two previously unidentified mutations in CDHR1. In particular, genetic anal-
ysis in family RP-0763 revealed a homozygous, and the sole missense mutation in exon 15 (c.1720C > G, 
p.P574A) reported so far in this gene being associated with any type of ocular pathology. In family 
RP-0043 we report a homozygous splice site mutation c.1485 + 2T > C, having an impact on the second 
fully conserved nucleotide position of the donor splice site of exon 13.
Clinically, the diagnosis of these patients is consistent with a form of CDHR1-related retinopathy. 
Different autosomal recessive phenotypes have been associated with mutations in the CDHR1 gene, rang-
ing from RP to CRD2,11,17–19. For the RP-0763 family, although the index case (II:2) refers photophobia, 
photopsia and color vision disturbances as first noticeable symptoms, she keeps a good visual acuity. 
Therefore, the phenotype of this patient seems to resemble more RP rather than CRD, or a diffuse ret-
inal dystrophy involving at the same time cones and rods. Overall, the phenotype of family RP-0763, 
harboring the missense mutation p.P574A, is less severe, at least in terms of BCVA, when compared with 
RP-0043 and the phenotypes described in literature2,11,17–19.
CDHR1 has been shown to be an important protein not only for photoreceptor homeostasis but 
also for photoreceptor development. It is present at the base of the backbone of the photoreceptor outer 
segment, localized at the developing discs. Its precise function has not been fully elucidated, but it has 
been shown that the role of CDHR1 is orchestrated via the use of its extracellular cadherin domains33,14. 
Ablation of cdhr1 in a mouse model results in functional consequences for the photoreceptors, lead-
ing to disarray of the outer segment and consequent photoreceptor degeneration and death15. To date, 
seven different mutations (including the ones reported in this study) have been identified in CDHR1 
(Fig. 4b)2,11,17–19. Interestingly, six of them are reported to result in premature stop codons which most 
likely lead to mRNA nonsense mediated decay and thus to no or trace protein product.
In CDHR1, the p.P574A mutation is topologically located at the end of the fifth ectodomain (EC), 
overlapping the linker region that joins the two neighboring cadherin ECs. Proline 574 is highly con-
served across species (Fig. 4a), an element that denotes its functional importance over evolution at this 
specific location. The linker regions in cadherins are hypothesized to play a crucial role in protein stabil-
ity but also in their structural integrity and function. They maintain the local ectodomain architecture 
via interactions with Ca2+, reinforcing the resulting EC suprastructures and preventing protein instability 
and immature proteolysis34,35. The replacement of proline with alanine, two residues with completely 
different biochemical profiles can be assumed to be destructive for the different functions that the linker 
region exerts. Moreover, corroborating the notion of the pathogenic nature of this mutation, three differ-
ent independent in silico web-based tools (SIFT, Polyphen and Mutation Taster) predict with high score 
the p.P574A missense change as disease causing.
The c.1485 + 2T > C is the second splice site mutation reported in CDHR1 to date17, affecting the same 
nucleotide position at the boundaries of exon 13 and intron 13 as previously reported. However, the base 
change differs. Based on the in silico prediction, the canonical splicing site is significantly knocked down 
Genomic location
Prediction 
software Wt sequence
Mutant 
sequence
Reference 
score 
Mutation 
score
Variation 
(%)
Chr10: 85,970,922–85,970,923
HSF
acagtggg acagcggg
2.99 − 4.75 − 285.86
NetGene2 0.273 0.043 15.75
Table 3.  In silico analysis of CDHR1 intron 13 donor splice site potential as predicted by NetGene 
2 Server and the Human Splicing Finder (HSF) analysis tools. The nucleotide position of the donor 
splice site is provided based on the human reference sequence (hg19). The two invariant nucleotides of the 
canonical 5′ splice site are bolded in the wild-type (wt) sequence. The mutant nucleotide is underlined in 
the box of the mutant sequence. The reference score refers to the wt sequence of the donor splice site. The 
Mutations Scores refers to the mutant sequence of the donor splice site. The Variation index measures the 
ratio of the mutation score divided by the reference score, expressed as a percentage.
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by this DNA change, likely leading to incorrect splicing and to an aberrant CDHR1 mRNA that should 
be subject to mRNA nonsense mediated decay.
In summary, in this work we delineate the retinal pathology of two families segregating autosomal 
recessive retinal dystrophy due to two previously undescribed mutations in CDHR1, one of which is the 
first pathogenic missense change described to date in this gene. With our findings, we provide further 
insight into the disease clinical and molecular portrait attributed to CDHR1.
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